Scott Meyers joins Vertice Pharma as Chief Operating Officer

Berkeley Heights, NJ., February 22, 2016 /PRNewswire/ -- Vertice Pharma today announced the appointment of Scott Meyers as Chief Operating Officer.

"We are pleased to welcome Scott to the Vertice Pharma leadership team. Scott brings over 15 years of progressive leadership experience and a strong track record of driving top tier performance. I am confident that Scott will provide immediate leadership and focus to a range of initiatives which will support our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.

"I am delighted to have the opportunity to join a talented leadership team at Vertice Pharma with their commitment to people, customers and growth," said Mr. Meyers.

Most recently, Scott has served as Vice President and General Manager, Dermatology of Fougera Inc., (a Sandoz / Novartis company). Prior to it, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company’s pharmaceutical practice in New Jersey, focusing on R&D and commercial operations. Scott also worked as a Chemical Engineer for Merck at their West Point, PA.

Scott holds a Master of Business Administration from Northwestern University’s Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.

About Vertice Pharma

Vertice Pharma is a specialty pharmaceuticals company focused on improving patients' health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey. For more information visit www.verticepharma.com

Media Contact:

Vertice Pharma

Kellen Johnson - Kellen.Johnson@verticepharma.com

Dr. Indranil Nandi joins Vertice Pharma as Vice President, Research & Development

Berkeley Heights, NJ., January 25, 2016 /PRNewswire/ -- Vertice Pharma today announced that it has appointed Dr. Indranil Nandi as Vice President, Research & Development effective today.

"We are delighted to welcome Dr. Nandi to the Vertice Pharma leadership team. Dr. Nandi brings over 15 years of extensive multi-disciplinary expertise in drug development and portfolio management across a broad range of therapeutic areas and dosage forms. Dr. Nandi has a proven track record in drug development and I have every confidence in his ability to lead Vertice’s Research & Development efforts. His extensive network and his experience in progressing collaborative projects will be key to building an even more robust product pipeline and driving our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.

"I am thrilled to be joining Vertice Pharma at such an exciting time and I look forward to growing our product pipeline with Don and the entire Vertice Pharma leadership team." Most recently, Dr. Nandi has served as Vice President, Generic Research & Development for Impax Laboratories. Prior to joining Impax, Dr. Nandi held positions of increasing responsibilities at Sandoz, including his last position as Executive Director, Portfolio, Project Management and Scientific Affairs. He also worked in various positions in R&D at Par Pharmaceuticals and Geneva Pharmaceuticals.

Dr. Nandi earned a Master of Business Administration from Rutgers, State University of NJ; a Ph.D. in Pharmaceutical Sciences from St. John’s University, NY and a Master’s degree in Pharmacy from Birla Institute of Technology and Sciences in India, and has co-authored various scientific publications and patents and patent applications.

About Vertice Pharma Vertice Pharma is a specialty pharmaceuticals company focused on improving patients' health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey. For more information visit www.verticepharma.com

Media Contact:

Vertice Pharma Kellen Johnson - Kellen.Johnson@verticepharma.com

Vertice Pharma Completes Acquisition of VistaPharm

Vertice Pharma, a specialty pharmaceuticals company focused on improving patients’ health, today announced it closed on the previously announced acquisition of VistaPharm, a specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics. Terms of the transaction were not disclosed.

The transaction was announced on November 17th along with the formation of Vertice Pharma and its partnership with and line of equity investment of up to $300 million from Warburg Pincus, a leading global private equity firm focused on growth investing. Vertice Pharma focuses on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.

Don DeGolyer, Chief Executive Officer, Vertice Pharma commented, “We are excited to have acquired VistaPharm. We look forward to working with the talented team of employees and continuing to develop the high quality products that our customers and patients have come to expect.”

About Vertice Pharma

Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.

For more information visit www.verticepharma.com

About VistaPharm

Formed in 1998, VistaPharm is a Largo, Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting.

Pharma Industry Veterans Launch Vertice Pharma in Partnership with Warburg Pincus; Announce Acquisition of VistaPharm

Warburg Pincus to Invest up to $300 Million to Build Leading Specialty Pharmaceuticals Platform


NEW YORK (November 17, 2015) – Pharmaceutical industry veterans Don DeGolyer and Andrew Saik today announced that they have launched Vertice Pharma, LLC (“Vertice Pharma” or “the Company”) in partnership with Warburg Pincus, a global private equity firm focused on growth investing. Vertice Pharma, utilizing a line of equity investment of up to $300 million from Warburg Pincus, will focus on acquiring specialty pharmaceutical companies and products, including both branded and generic products, to create a durable specialty pharmaceutical business of scale.


Mr. DeGolyer will serve as Chief Executive Officer (CEO) of Vertice Pharma, and Mr. Saik will serve as Chief Financial Officer (CFO). Mr. DeGolyer most recently served as Chief Operating Officer at Endo Pharmaceuticals, where he led its branded and generics businesses and oversaw several key acquisitions. Prior to that, Mr. DeGolyer served as President and CEO of North America for Sandoz, Novartis' generic pharmaceuticals unit. Mr. Saik was most recently Chief Financial Officer at Auxilium Pharmaceuticals, where he helped lead the execution of the company’s growth strategy and successful $2.3 billion sale to Endo. The senior leadership team also includes several executives who have proven track records of value creation in the pharmaceutical industry.


Mr. DeGolyer commented, “We share Warburg Pincus’ vision to build a business that can acquire and develop branded and generic specialty pharmaceuticals and work to maximize their potential. With the attractive long-term fundamentals in the specialty pharmaceutical industry and the depth of our collective network with Warburg Pincus, we believe Vertice Pharma is very well positioned.”


Fred Hassan, Managing Director, Healthcare, Warburg Pincus, added, “There is an opportunity in this sector to create significant value in key branded and generic assets by investing in development to drive revenues and improving operations. Don, Andrew and the rest of the Vertice Pharma team are the ideal partners to do just that and we look forward to supporting them.”


Vertice Pharma also announced it has reached a definitive merger agreement to acquire VistaPharm, a specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics. Terms of the transaction were not disclosed.


Mr. DeGolyer continued, “Acquiring a company with the caliber of products and talent that VistaPharm has is exactly what we envisioned when we teamed up with Warburg Pincus. We are pleased to have this opportunity come to fruition so quickly. We look forward to working with VistaPharm’s outstanding employees to build on the company’s success.”


John Schutte, Chairman and CEO of VistaPharm commented, “We are proud of the quality products and knowledgeable service that our customers have come to expect when caring for their patients. Vertice Pharma recognizes the value we bring to our customers and we are excited to join forces with Don and his team.” 

VistaPharm will maintain its manufacturing and distribution facilities in Largo, Florida. The companies expect the transaction to close no later than the first quarter of 2016.

Jefferies served as exclusive financial advisor to Vertice Pharma. Simpson Thacher & Bartlett acted as legal advisors to Warburg Pincus.


About Vertice Pharma
Vertice Pharma is a specialty pharmaceuticals company focused on improving patients’ health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies. Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.


About Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $35 billion in assets under management. The firm’s active portfolio of more than 120 companies is highly diversified by stage, sector and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 14 private equity funds, including a $4 billion energy fund that closed in October 2014, which have invested more than $50 billion in over 720 companies in more than 35 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Frankfurt, Hong Kong, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo and Shanghai. For more information please visit www.warburgpincus.com.


About VistaPharm
Formed in 1998, VistaPharm is a Largo, Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting.


Media Contacts:
 

For Vertice Pharma
Kellen Johnson
Kellen.Johnson@verticepharma.com

For Warburg Pincus
Ed Trissel
212.878.9288
Mary Zimmerman
212.878.9207